SENECA study summarized by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“FOLFIRI vs. CapTem in the second line after platinum/etoposid for NECs
SENECA study

The two regimens showed comparable activity

• GEP and lung NECs
  
• 12 weeks-Disease Control Rate 39.1% vs 28%
  
• 12 mo OS 28.4% vs 32.4%
  
• FOLFIRI: neutropenia, anemia
  
• CapTem: thrombocytopenia, nausea/vomiting

The study was halted for futility as the minimum 12w-DCR threshold of 10 out of 25 patients was not reached.”

Source: Erman Akkus/X